Global Hereditary Angioedema Treatment Market Overview:
Global Hereditary Angioedema Treatment Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Hereditary Angioedema Treatment Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Hereditary Angioedema Treatment involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Hereditary Angioedema Treatment Market:
The Hereditary Angioedema Treatment Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Hereditary Angioedema Treatment Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Hereditary Angioedema Treatment Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Hereditary Angioedema Treatment market has been segmented into:
C1 Esterase Inhibitor Replacement Therapy
Bradykinin B2 Receptor Antagonists
Recombinant C1 Esterase Inhibitor
Blood Plasma Derived Therapies
By Application, Hereditary Angioedema Treatment market has been segmented into:
Intravenous
Subcutaneous
Oral
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Hereditary Angioedema Treatment market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Hereditary Angioedema Treatment market.
Top Key Players Covered in Hereditary Angioedema Treatment market are:
Ionis Pharmaceuticals
Pfizer
H Genzyme
Revance Therapeutics
Eurordis
Baxter
Sobi
Portola Pharmaceuticals
Amgen
Biocryst Pharmaceuticals
ViroPharma
Takeda
CSL Behring
Shire
Sanofi
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Hereditary Angioedema Treatment Market Type
4.1 Hereditary Angioedema Treatment Market Snapshot and Growth Engine
4.2 Hereditary Angioedema Treatment Market Overview
4.3 C1 Esterase Inhibitor Replacement Therapy
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 C1 Esterase Inhibitor Replacement Therapy: Geographic Segmentation Analysis
4.4 Bradykinin B2 Receptor Antagonists
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Bradykinin B2 Receptor Antagonists: Geographic Segmentation Analysis
4.5 Recombinant C1 Esterase Inhibitor
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Recombinant C1 Esterase Inhibitor: Geographic Segmentation Analysis
4.6 Blood Plasma Derived Therapies
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Blood Plasma Derived Therapies: Geographic Segmentation Analysis
Chapter 5: Hereditary Angioedema Treatment Market Application
5.1 Hereditary Angioedema Treatment Market Snapshot and Growth Engine
5.2 Hereditary Angioedema Treatment Market Overview
5.3 Intravenous
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Intravenous: Geographic Segmentation Analysis
5.4 Subcutaneous
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Subcutaneous: Geographic Segmentation Analysis
5.5 Oral
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Oral: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Hereditary Angioedema Treatment Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 IONIS PHARMACEUTICALS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 PFIZER
6.4 H GENZYME
6.5 REVANCE THERAPEUTICS
6.6 EURORDIS
6.7 BAXTER
6.8 SOBI
6.9 PORTOLA PHARMACEUTICALS
6.10 AMGEN
6.11 BIOCRYST PHARMACEUTICALS
6.12 VIROPHARMA
6.13 TAKEDA
6.14 CSL BEHRING
6.15 SHIRE
6.16 SANOFI
Chapter 7: Global Hereditary Angioedema Treatment Market By Region
7.1 Overview
7.2. North America Hereditary Angioedema Treatment Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 C1 Esterase Inhibitor Replacement Therapy
7.2.2.2 Bradykinin B2 Receptor Antagonists
7.2.2.3 Recombinant C1 Esterase Inhibitor
7.2.2.4 Blood Plasma Derived Therapies
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Intravenous
7.2.3.2 Subcutaneous
7.2.3.3 Oral
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Hereditary Angioedema Treatment Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 C1 Esterase Inhibitor Replacement Therapy
7.3.2.2 Bradykinin B2 Receptor Antagonists
7.3.2.3 Recombinant C1 Esterase Inhibitor
7.3.2.4 Blood Plasma Derived Therapies
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Intravenous
7.3.3.2 Subcutaneous
7.3.3.3 Oral
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Hereditary Angioedema Treatment Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 C1 Esterase Inhibitor Replacement Therapy
7.4.2.2 Bradykinin B2 Receptor Antagonists
7.4.2.3 Recombinant C1 Esterase Inhibitor
7.4.2.4 Blood Plasma Derived Therapies
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Intravenous
7.4.3.2 Subcutaneous
7.4.3.3 Oral
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Hereditary Angioedema Treatment Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 C1 Esterase Inhibitor Replacement Therapy
7.5.2.2 Bradykinin B2 Receptor Antagonists
7.5.2.3 Recombinant C1 Esterase Inhibitor
7.5.2.4 Blood Plasma Derived Therapies
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Intravenous
7.5.3.2 Subcutaneous
7.5.3.3 Oral
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Hereditary Angioedema Treatment Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 C1 Esterase Inhibitor Replacement Therapy
7.6.2.2 Bradykinin B2 Receptor Antagonists
7.6.2.3 Recombinant C1 Esterase Inhibitor
7.6.2.4 Blood Plasma Derived Therapies
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Intravenous
7.6.3.2 Subcutaneous
7.6.3.3 Oral
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Hereditary Angioedema Treatment Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 C1 Esterase Inhibitor Replacement Therapy
7.7.2.2 Bradykinin B2 Receptor Antagonists
7.7.2.3 Recombinant C1 Esterase Inhibitor
7.7.2.4 Blood Plasma Derived Therapies
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Intravenous
7.7.3.2 Subcutaneous
7.7.3.3 Oral
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Hereditary Angioedema Treatment Scope:
|
Report Data
|
Hereditary Angioedema Treatment Market
|
|
Hereditary Angioedema Treatment Market Size in 2025
|
USD XX million
|
|
Hereditary Angioedema Treatment CAGR 2025 - 2032
|
XX%
|
|
Hereditary Angioedema Treatment Base Year
|
2024
|
|
Hereditary Angioedema Treatment Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Ionis Pharmaceuticals, Pfizer, H Genzyme, Revance Therapeutics, Eurordis, Baxter, Sobi, Portola Pharmaceuticals, Amgen, Biocryst Pharmaceuticals, ViroPharma, Takeda, CSL Behring, Shire, Sanofi.
|
|
Key Segments
|
By Type
C1 Esterase Inhibitor Replacement Therapy
Bradykinin B2 Receptor Antagonists
Recombinant C1 Esterase Inhibitor
Blood Plasma Derived Therapies
By Applications
Intravenous
Subcutaneous
Oral
|
